| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.14.164 |
| P698 | PubMed publication ID | 25471031 |
| P50 | author | Alexander Weng | Q47101532 |
| P2093 | author name string | Mayank Thakur | |
| Hendrik Fuchs | |||
| Horst Dürkop | |||
| Winfried Brenner | |||
| Matthias F Melzig | |||
| Mathias Lukas | |||
| Benedicta von Mallinckrodt | |||
| Nicola Beindorff | |||
| Roger Gilabert-Oriol | |||
| P2860 | cites work | Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs | Q28246401 |
| Antibody therapy of cancer | Q28262538 | ||
| Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression. | Q30352191 | ||
| Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma | Q33367113 | ||
| Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Q33515519 | ||
| Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis | Q33530754 | ||
| Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer | Q34094717 | ||
| Comparing antibody and small-molecule therapies for cancer | Q34560075 | ||
| Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors | Q34624887 | ||
| Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development | Q35761426 | ||
| Immunotoxins and other conjugates: pre-clinical studies | Q35794017 | ||
| EGFR and colon cancer: a clinical view. | Q37061584 | ||
| Worldwide variations in colorectal cancer | Q37629430 | ||
| Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. | Q37681223 | ||
| Prediction in rectal cancer. | Q37990115 | ||
| A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins | Q38360421 | ||
| Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells | Q39094126 | ||
| Macromolecular interactions of triterpenoids and targeted toxins: role of saponins charge. | Q39120335 | ||
| Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: an evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice. | Q39214329 | ||
| Saponins modulate the intracellular trafficking of protein toxins | Q39260090 | ||
| Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies | Q39281507 | ||
| Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin | Q39327678 | ||
| The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins. | Q39656007 | ||
| A convenient method for saponin isolation in tumour therapy. | Q39741760 | ||
| A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice | Q40185880 | ||
| In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. | Q40345495 | ||
| A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake | Q40407709 | ||
| Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts | Q40664427 | ||
| Sex Hormones and Colorectal Cancer: What Have We Learned So Far? | Q42338932 | ||
| Dianthins, ribosome-damaging proteins with anti-viral properties from Dianthus caryophyllus L. (carnation). | Q45819212 | ||
| Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. | Q45937932 | ||
| Recommendations on the use of 18F-FDG PET in oncology | Q46744015 | ||
| Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. | Q54309905 | ||
| Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement. | Q54517629 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | xenograft | Q64148587 |
| P304 | page(s) | 2161-2175 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma | |
| P478 | volume | 10 |
| Q26744722 | Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers |
| Q90722185 | Dianthin and Its Potential in Targeted Tumor Therapies |
| Q38703584 | Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma |
| Q50985144 | Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies. |
| Q41918293 | Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions). |
| Q38899428 | Recent progress in protein-protein interaction study for EGFR-targeted therapeutics |
| Q28072394 | Structures and Ribosomal Interaction of Ribosome-Inactivating Proteins |
| Q47101471 | Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861. |
Search more.